Search clinical trials for: DAY101

Total 201 results

Day One Biopharmaceuticals, Inc.

Available

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Low-grade Glioma
Karen D. Wright, MD
National Cancer Institute (NCI); Pacific Pediatric Neuro-Oncology Consortium; Day One Biopharmaceuticals, Inc... and other collaborators

Active, not recruiting

DAY101 In Gliomas and Other Tumors

Low-grade Glioma

United States
Day One Biopharmaceuticals, Inc.
Pacific Pediatric Neuro-Oncology Consortium

Recruiting

A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1)

Advanced Solid Tumor | Low-grade Glioma

United States, Israel, Korea, Republic of, Denmark, Singapore, Netherlands, Canada, Australia, Germany, Switzerland, United Kingdom
Ansun Biopharma, Inc.

Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19 | Lower Respiratory Tract Infection | Immunocompromised | Parainfluenza

United States, Australia, China, Denmark, France, Hong Kong, Korea, Republic of, Taiwan
National Institute of Allergy and Infectious Diseases...

Withdrawn

DAS181 in Patients With Parainfluenza

Parainfluenza Infection
Ansun Biopharma, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

DAS181 Single Dose Escalation Study in Healthy Adults

Healthy

United States
Ansun Biopharma, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Single Dose Escalating Study of DAS181 in Adults

Influenza

United States
Ansun Biopharma, Inc.

Completed

Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza

Influenza

United States
Renmin Hospital of Wuhan University
Ansun Biopharma, Inc.

Completed

DAS181 for Severe COVID-19: Compassionate Use

COVID-19

China
Ilypsa

Unknown

Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia

Kidney Diseases | Renal Insufficiency

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (SMART)

Spinal Muscular Atrophy

Taiwan, Belgium, Canada, United States, Australia, France, Italy, Portugal, United Kingdom
Dynacure

Withdrawn

Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies (DyNaMic)

Centronuclear Myopathy

Germany, France
Ansun Biopharma, Inc.

Withdrawn

DAS181 for STOP COVID-19

COVID-19

Italy
Ansun Biopharma, Inc.

Unknown

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) (STOP-Flu)

Influenza Infection | SAD-RV Infection and COVID-19

China
Children's Oncology Group

Not yet recruiting

A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis
Aimmune Therapeutics, Inc.

Completed

AR101 Real-World Open-Label Extension Study

Peanut Allergy

United States, Canada
Allecra

Completed

Single Dose Mass Balance Study With C14 - Labeled AAI101 in Healthy Male Volunteers

Healthy

United States
Astellas Pharma Inc

Completed

Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

Renal Insufficiency | Chronic Kidney Disease | Hyperphosphatemia | Renal Dialysis

Japan
Astellas Pharma Inc

Completed

A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis

Renal Insufficiency | Chronic Kidney Disease | Renal Dialysis

Japan
Sunshine Lake Pharma Co., Ltd.

Completed

The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects

Chronic Hepatitis c

China
Day One Biopharmaceuticals, Inc.
SIOPe Brain Tumor Group LOGGIC Consortium

Recruiting

DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Low-grade Glioma

United States, Korea, Republic of, France, Germany, Spain, United Kingdom, Belgium, Denmark, Canada, Italy, Finland, Australia, Ireland, Switzerland, Netherlands, Czechia, Greece, New Zealand, Slovenia, Sweden, Hungary, Singapore, A... and more
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Peking University People's Hospital

Completed

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China
Astellas Pharma Inc

Completed

Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients

Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis

Japan
Akeso

Completed

A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

China
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA) (OFELIA)

Muscular Atrophy, Spinal

Brazil, Argentina
Alladapt Immunotherapeutics, Inc.

Completed

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

Food Allergy

United States
Ayala Pharmaceuticals, Inc,

Terminated

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY)

Triple Negative Breast Cancer

United States, Belgium, Israel, Spain, United Kingdom
Aimmune Therapeutics, Inc.

Completed

PALISADE Follow-on Study (ARC004)

Peanut Allergy

United States, Spain, Netherlands, Italy, Canada, Germany, Ireland, Sweden, United Kingdom
Astellas Pharma Inc

Completed

Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis

Chronic Renal Failure

Japan
Aimmune Therapeutics, Inc.

Terminated

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Peanut Allergy

Spain
Akeso

Completed

A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis

Psoriasis Vulgaris

China
VitNovo, Inc.

Completed

DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients

Type2 Diabetes

Taiwan
Patara Pharma

Completed

Treatment of Refractory Chronic Cough With PA101

Refractory Chronic Cough

Netherlands, United Kingdom
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Peanut Allergy

United States
Astellas Pharma Inc

Completed

Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Renal Insufficiency | Chronic Kidney Disease | Hyperphosphatemia

Japan
Ansun Biopharma, Inc.

Completed

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection (PIV)

Parainfluenza

United States
Alladapt Immunotherapeutics, Inc.

Terminated

Open-label Extension Study of ADP101

Food Allergy

United States
Chugai Pharmaceutical

Not yet recruiting

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS) | Immune Thrombocytopenia (ITP) | Dermatomyositis (DM) | Bullous Pemphigoid (BP) | Behçet's Syndrome (BS) | Immune-mediated Necrotizing Myopathy (IMNM)

United States, Japan
Astellas Pharma Inc

Completed

Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease

Chronic Kidney Disease

Japan
Namyi Gu

Completed

The Effect of DA9301 on Tablet Computer-Induced Asthenopia

Asthenopia
University of Alabama at Birmingham

Not yet recruiting

Effects of Sustained-release Oral Sodium Nitrite on Postoperative Pain and Recovery Following Total Knee Arthroplasty

Pain
Aimmune Therapeutics, Inc.

Completed

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (RAMSES)

Peanut Allergy

United States, Canada
Tayu Huaxia Biotech Medical Group Co., Ltd.

Recruiting

A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Locally Advanced /Metastatic Solid Tumors | Relapsed or Refractory Lymphomas

China
Astellas Pharma Inc

Completed

A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Renal Insufficiency | Chronic Kidney Disease | Hyperphosphatemia

Japan
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Recruiting

A Study of QY101 Ointment in Subjects With Plaque Psoriasis

Psoriasis

China
Akeso

Recruiting

Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis

Plaque Psoriasis

China
Ansun Biopharma, Inc.
National Institutes of Health (NIH)

Completed

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis (DAS181)

Bronchiectasis | Asthma

United States
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) (STEER)

Type 2 Spinal Muscular Atrophy

United States, China, Saudi Arabia, Thailand, Singapore, Brazil, Malaysia, Taiwan, Colombia, Mexico, Denmark, Egypt, India, South Africa, Vietnam
Dynacure

Terminated

Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies (Unite-CNM)

Centronuclear Myopathy

France, Netherlands, United Kingdom, Belgium, Denmark, Germany
Novartis Gene Therapies

Completed

Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1 (STRIVE-EU)

SMA

France, United Kingdom, Italy, Belgium

Search clinical trials for: DAY101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations